Dermatology
FDA/CDC
FDA updates hydrochlorothiazide label to include nonmelanoma skin cancer risk
Patients should continue taking the antihypertensive drug unless their doctor says otherwise, according to an FDA...
News
Cutaneous clues linked to COVID-19 coagulation risk
These skin signs could augment coagulation assays in this patient population.
News
New psoriasis guidelines focus on topical and alternative treatments, and severity measures
The latest updated psoriasis treatment guidelines address topicals, alternative medicine, and severity assessment.
Opinion
COVID-19–related skin changes: The hidden racism in documentation
It is not a stretch to suggest that skin manifestations associated with COVID-19 may look very different in darker skin.
News
More data needed to better understand COVID-19 skin manifestations
Histopathologic exams were done for only 23 patients and, in all cases, showed “inflammatory features without specific pathological changes.”
News
Is the presence of enanthem a clue for COVID-19?
In the study, six of the patients presented with oral lesions, all of them located in the palate.
News
Doctors hesitated to embrace biosimilar infliximab in first 2 years
Adoption of biosimilar infliximab was initially slow, but more widely used in new patients.
News
Lifestyle changes may explain skin lesions in pandemic-era patients
"Dermatologists must be aware of the protean cutaneous findings that are possibly associated with COVID-19, even if our understanding of their...
Conference Coverage
Skin patterns of COVID-19 vary widely
“There’s a lot that we still don’t know, and some patterns are going to be outliers,” Dr. Christine Ko said.
News
COVID-19 complicates prescribing for children with inflammatory skin disease
Pediatric dermatologists say they would continue children on most immunosuppressive treatments, but are more reluctant to initiate.